VIIV-HEALTHCARE
ViiV Healthcare and Shutterstock Studios today announced the launch of a new online photo gallery ‘HIV in View’ , produced by Shutterstock in collaboration with ViiV Healthcare. The collection, curated with the support of people living with HIV, leverages Shutterstock’s global network of over one million creators to deliver a repository of high-resolution images depicting what it means to live with HIV today. Across four countries (the United Kingdom, Kenya, Uruguay, Portugal), people living with HIV stepped forward to be among the first photographed for this gallery, embarking on a shared ambition to help shift the world’s perception of HIV and move away from outdated stereotypes. From World AIDS Day 2020, the gallery will be free for all to access and use in projects, campaigns and communications* in the hope that it will increase awareness around HIV and break down barriers to stigma that still exist.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005521/en/
Doreen Moracha, aged 28, from Nairobi, Kenya, one of the first people to be photographed for the gallery and HIV Advocate, said , “I am so proud to be one of the first people to be photographed for the ‘HIV in View’ gallery and to be part of a movement for change to represent real people living with HIV, their stories and experiences. Until the world sees HIV for what it really is, we are not going to make the progress we need to disrupt stereotypes of what it’s like to live with HIV. If my photographs can change just one person’s opinion of what it means to live with HIV today, I will know we are a step closer to reaching this goal.”
Today, living with HIV is a very different experience from just ten years ago. Advances in prevention, treatment and care mean that people living with HIV can live longer, healthier lives, with a person starting treatment at 20 years old now able to expect to see their 77th birthday.1 Despite these advances, people living with HIV face unique challenges that affect their quality of life every day. Stigma remains a stubbornly persistent threat to the health and well-being of many people living with HIV, and can often impact their ability to consistently access life-saving treatments and social support systems.2 In the battle to challenge the negative assumptions about HIV, shining a light on the truth can be a potent strategy. Sharing the true picture and experiences of people living with HIV is key to undermining stigma.
Deborah Waterhouse, CEO, ViiV Healthcare, said, “At ViiV Healthcare, our mission is to leave no person living with HIV behind and reducing HIV-related stigma is key to achieving this. For too long, the public has been presented with outdated representations of what it is to live with HIV. Working with Shutterstock has underlined how a lack of widely accessible, present-day HIV imagery continues to hold us back. With the launch of the ‘HIV in View’ gallery, people across the world can now download authentic photography for free. As a company, we are making a pledge to use images of real people living with HIV across all our platforms, where applicable, moving forward and we encourage others to do the same. Living with HIV has changed, and we invite the world to help us show this.”
Michael Carfagnini, GM Global Shutterstock Studios, said, “ViiV Healthcare’s work in continuing to fight HIV-related stigma until people living with HIV are understood and accepted sparked a unique opportunity for Shutterstock to collaborate through powerful visuals. There is always a need for authentic and fresh imagery accurately depicting what it's like to live with HIV. At Shutterstock, we strive to empower the world’s storytellers through our content and services such as those offered through our new Studios division enabling brands and agencies to tell their unique stories. This presented an opportunity to prove the effectiveness and adaptability of our global network of contributors who would be tasked with safely depicting this crucial story, in a much more challenging time to do photography and videography with a pandemic limiting production around the world. This project and the various teams involved both at Shutterstock and ViiV Healthcare truly demonstrated the impact passion brings to creative projects, and we saw the same quality from our contributors and people living with HIV featured in the imagery.”
The ‘HIV in View’ gallery is produced by Shutterstock and created in collaboration with ViiV Healthcare. All images can be downloaded royalty free here: https://www.shutterstock.com/explore/viiv-collaboration .
Notes to editor
*The HIV in View collection will be offered for free under Shutterstock’s standard license to use in projects, campaigns and communications. Users who require the enhanced license will be charged the higher license fee, of which 100% of the proceeds will be donated to (RED), a non-profit organisation helping fund the fight to end AIDS, at the discretion of Shutterstock. For additional information on the license comparison, visit: https://www.shutterstock.com/license-comparison .
About Shutterstock, Inc.
Shutterstock, Inc. (NYSE: SSTK ), directly and through its group subsidiaries, is a leading global provider of high-quality licensed photographs , vectors , illustrations , videos and music to businesses, marketing agencies and media organizations around the world. Working with its growing community of over 1 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 350 million images and more than 20 million video clips available.
Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The company’s brands also include Bigstock , a value-oriented stock media offering; Shutterstock Custom, a custom content creation platform ; Offset, a high-end image collection ; PremiumBeat, a curated royalty-free music library ; and Shutterstock Editorial, a premier source of editorial images and videos for the world's media.
For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook .
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com .
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us .
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q3 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
1. May et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Available at: https://pubmed.ncbi.nlm.nih.gov/24556869/ Last accessed: December 2020.
2. Avert. HIV stigma and discrimination. Available at: https://www.avert.org/professionals/hiv-social-issues/stigma-discrimination Last accessed: December 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 07:00:00 CEST | Press release
Results from a real-world clinical study conducted in China, to be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, reveal that modern lifestyles and environmental triggers significantly impact individuals with sensitive skin1 Data show that people with sensitive skin living in modern environments have higher levels of inflammation compared to those living traditional, less stressful lifestyles1 This first-of-its-kind study was conducted by Galderma’s Global Sensitive Skincare Faculty (GSSF) as part of the company’s commitment to transforming the understanding and care of sensitive skin1 Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be pres
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 06:24:00 CEST | Press release
Expanded direct connection enables Alipay+ to help global wallets build China merchant networkAnt is the largest player in the CPG scheme in terms of coverage, use cases and business volume Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom